Previous 10 | Next 10 |
home / stock / sva:cc / sva:cc news
LONDON, Ontario, April 10, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced that President and Chief Executive Officer, Dr. Philip Toleikis, will present at the upcoming annual Cell & Gene...
The dissident director nominees declined to follow proper protocol to participate in Sernova’s board renewal process and instead are imposing themselves on the Company through a costly and disruptive proxy battle Management and the Board have placed Sernova in a position to bring v...
Concerned Shareholders of Sernova Corp. Nominate Two Highly Qualified Directors to the Board Canada NewsWire Concerned shareholder group has issued an information circular and letter to shareholders outlining reasons for change TORONTO , April 3, 2023 /CN...
LONDON, Ontario, March 22, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, is pleased to announce that an abstract has been selected for an oral podium presentation at the upcoming American Diabetes Associat...
LONDON, Ontario, March 14, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced today that an abstract has been selected for an oral presentation at the 4 th International Pancreas and Islet Transpl...
Third patient now implanted with higher capacity, 10-chamber Cell Pouch Company anticipates first interim data from second cohort in Q4 2023 LONDON, Ontario, March 08, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and le...
LONDON, Ontario, March 02, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced it will be participating in the upcoming 35th Annual Roth Conference being held March 12-14, 2023 and the Oppenheime...
Sernova (TSX: SVA) is a clinical-stage biotechnology company developing therapeutic cell technologies with a goal to deliver a 'functional cure' for chronic diseases, including insulin-dependent diabetes, thyroid disease and hemophilia A. Sernova has developed the Cell Pouch System(TM), an impla...
Preclinical proof of concept study demonstrates that thyroid auto-transplantation into the Cell Pouch can restore thyroid hormone production following removal of the thyroid gland Sernova has engaged with regulatory authorities towards initiating clinical development of a prospective therapy ...
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia iPSC islet-like cluster manufacturing scale-up and te...
News, Short Squeeze, Breakout and More Instantly...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – TheNewswire - July 15, 2024 – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatment o...
(TheNewswire) To date Sernova reports 7 patients in its Phase I/II type 1 diabetes clinical trial achieved freedom from insulin injections and demonstrate blood sugar control in the non- diabetic range (HbA1c 6.5%); 6 patients have reached between 5.5 and 50 months o...
(TheNewswire) LONDON, Ontario; BOSTON, Massachusetts – June 12, 2024 – TheNewswire – Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage biotechnology company focused on the development of regenerative medicine cell therapies for treatmen...